ICLUSIG 45 mg, film-coated tablets 30 tablets
Active ingredients: Ponatinib hydrochloride, Ponatinib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ICLUSIG 45 mg, comprimés pelliculés
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s)
- Marketing authorisation holder
- INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Oct 2013
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63898099CIP72741982CIP133400927419829Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PONATINIBcomprimé | 45 mg · un comprimé | FT |
| CHLORHYDRATE DE PONATINIBcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.